James Fagin

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Molecular pathology of thyroid cancer: diagnostic and clinical implications
    James A Fagin
    Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Best Pract Res Clin Endocrinol Metab 22:955-69. 2008
  2. pmc Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease
    Iñigo Landa
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E1562-6. 2013
  3. pmc Genome-wide analysis of Pax8 binding provides new insights into thyroid functions
    Sergio Ruiz-Llorente
    Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientificas CSIC y Universidad Autonoma de Madrid UAM, c Arturo Duperier 4, Madrid 28029, Spain
    BMC Genomics 13:147. 2012
  4. pmc GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation
    Lars Wichmann Madsen
    Novo Nordisk A S, Novo Alle, DK 2880, Bagsvaerd, Denmark
    Endocrinology 153:1538-47. 2012
  5. doi request reprint Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Thyroid 20:1085-93. 2010

Research Grants

  1. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James A Fagin; Fiscal Year: 2010
  2. PARACRINE IGF/IGFBP INTERACTIONS IN VIVO
    James Fagin; Fiscal Year: 2002
  3. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James Fagin; Fiscal Year: 2007
  4. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James A Fagin; Fiscal Year: 2010
  5. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James Fagin; Fiscal Year: 2001
  6. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 2007
  7. Paracrine IGF/GFBP Interactions In Vivo
    James Fagin; Fiscal Year: 2007
  8. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 1999
  9. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 2004

Collaborators

  • Ronald A Ghossein
  • Norisato Mitsutake
  • Jeffrey A Knauf
  • Iñigo Landa
  • Sergio Ruiz-Llorente
  • Lars Wichmann Madsen
  • Ian Ganly
  • Michael Rivera
  • Timothy A Chan
  • Michiko Matsuse
  • Tihana Ibrahimpasić
  • Sushil Vundavalli
  • Ingrid Sjogren
  • Lotte Bjerre Knudsen
  • Søren Andersen
  • Carsten Gotfredsen
  • David G Pisano
  • Cristina Montero-Conde
  • Andrew Pilling
  • Anne Marie Moelck
  • Alfonso Valencia
  • Pilar Santisteban
  • Afsar Barlas
  • Anne Sietske de Boer
  • Lene Andersen
  • Ana Sastre-Perona
  • Gonzalo Gomez-Lopez
  • Niels C Berg Nyborg
  • Enrique Carrillo Santa de Pau
  • Katia Manova
  • Robert Michael Tuttle
  • Julio Ricarte-Filho
  • Ashok Shaha

Detail Information

Publications5

  1. pmc Molecular pathology of thyroid cancer: diagnostic and clinical implications
    James A Fagin
    Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Best Pract Res Clin Endocrinol Metab 22:955-69. 2008
    ..Based on preclinical evidence, mutations of genes encoding certain kinases may also predict response to specific tyrosine kinase inhibitors, although this has not yet been explored systematically in clinical trials...
  2. pmc Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease
    Iñigo Landa
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E1562-6. 2013
    ..Telomerase activity is required for cell immortalization. Somatic TERT promoter mutations modifying key transcriptional response elements were recently reported in several cancers, such as melanomas and gliomas...
  3. pmc Genome-wide analysis of Pax8 binding provides new insights into thyroid functions
    Sergio Ruiz-Llorente
    Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientificas CSIC y Universidad Autonoma de Madrid UAM, c Arturo Duperier 4, Madrid 28029, Spain
    BMC Genomics 13:147. 2012
    ..of thyroid cells, we obtained transcriptional profiles of Pax8-silenced PCCl3 thyroid cells using whole genome expression arrays and integrated these signals with global cis-regulatory sequencing studies performed by ChIP-Seq analysis..
  4. pmc GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation
    Lars Wichmann Madsen
    Novo Nordisk A S, Novo Alle, DK 2880, Bagsvaerd, Denmark
    Endocrinology 153:1538-47. 2012
    ..These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner...
  5. doi request reprint Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Thyroid 20:1085-93. 2010
    ..Our objective was to analyze ETE at the molecular and histologic levels and assess the effect of its extent on outcome...

Research Grants40

  1. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James A Fagin; Fiscal Year: 2010
    ....
  2. PARACRINE IGF/IGFBP INTERACTIONS IN VIVO
    James Fagin; Fiscal Year: 2002
    ..He will also study the effects of crossing these mice will the IGF transgenic mice to study the impact of co-expression on phenotype. ..
  3. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James Fagin; Fiscal Year: 2007
    ..This would be consistent with the notion that Ras mutation, in thyroid cells induce a "mutator" phenotype, and are thus more likely to undergo phenotypic progression. ..
  4. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James A Fagin; Fiscal Year: 2010
    ..This will help us decide what key genetic abnormalities to focus on as we develop specific treatments for patients with the most advanced forms of the disease. ..
  5. ONCOGENIC EVENTS IN THYROID NEOPLASIA
    James Fagin; Fiscal Year: 2001
    ..Finally, the role of mutations of PKC alpha in the control of thyroid-differentiated gene expression will be studied. ..
  6. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 2007
    ....
  7. Paracrine IGF/GFBP Interactions In Vivo
    James Fagin; Fiscal Year: 2007
    ..abstract_text> ..
  8. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 1999
    ....
  9. MOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTH
    James Fagin; Fiscal Year: 2004
    ..Activation of PLC-gamma can cause activation of PKC-epsilon, and this may possibly be involved in apoptosis. ..